Pfenex Company Profile (NYSEMKT:PFNX)

About Pfenex

Pfenex logoPfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NYSEMKT
  • Symbol: PFNX
  • CUSIP:
Key Metrics:
  • Previous Close: $7.82
  • 50 Day Moving Average: $8.29
  • 200 Day Moving Average: $8.77
  • 52-Week Range: $5.78 - $11.35
  • Trailing P/E Ratio: 24.51
  • Foreward P/E Ratio: -4.07
  • P/E Growth: 3.53
  • Market Cap: $183.13M
  • Outstanding Shares: 23,418,000
  • Beta: 4.65
Additional Links:
Companies Related to Pfenex:

Analyst Ratings

Consensus Ratings for Pfenex (NYSEMKT:PFNX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.00

Analysts' Ratings History for Pfenex (NYSEMKT:PFNX)
Show:
DateFirmActionRatingPrice TargetDetails
8/9/2016MizuhoLower Price TargetBuy$22.00 -> $18.00View Rating Details
5/24/2016Barclays PLCLower Price TargetOverweight$28.00 -> $14.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$25.00 -> $22.00View Rating Details
9/15/2015Evercore ISIInitiated CoverageBuyView Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Pfenex (NYSEMKT:PFNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/9/2016Q316($0.56)$1.46$3.18 million$48.82 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.43)$2.55 million$3.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.45)($0.35)$2.35 million$2.76 millionViewN/AView Earnings Details
3/10/2016Q415($0.59)($0.37)$2.56 million$3.30 millionViewListenView Earnings Details
11/13/2015Q315($0.46)($0.33)$2.05 million$2.06 millionViewListenView Earnings Details
8/13/2015Q215($0.39)($0.27)$2.07 million$2.30 millionViewListenView Earnings Details
5/14/2015Q115($0.24)($0.29)$2.10 million$2.00 millionViewListenView Earnings Details
3/16/2015Q4($0.20)($0.18)$2.05 million$2.02 millionViewN/AView Earnings Details
11/13/2014Q3($0.25)($0.16)$2.13 million$2.80 millionViewN/AView Earnings Details
9/2/2014($0.15)($1.67)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pfenex (NYSEMKT:PFNX)
Current Year EPS Consensus Estimate: $0.05 EPS
Next Year EPS Consensus Estimate: $-1.92 EPS

Dividends

Dividend History for Pfenex (NYSEMKT:PFNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pfenex (NYSEMKT:PFNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/6/2017Signet Healthcare Partners AccMajor ShareholderSell400$9.50$3,800.00View SEC Filing  
1/5/2017Signet Healthcare Partners AccMajor ShareholderSell7,710$9.50$73,245.00View SEC Filing  
12/29/2016Signet Healthcare Partners AccMajor ShareholderSell24,104$9.66$232,844.64View SEC Filing  
12/27/2016Signet Healthcare Partners AccMajor ShareholderSell104,600$9.58$1,002,068.00View SEC Filing  
12/22/2016Signet Healthcare Partners AccMajor ShareholderSell10,896$9.61$104,710.56View SEC Filing  
11/21/2016Patricia LadyInsiderSell2,000$9.87$19,740.00View SEC Filing  
11/15/2016Patrick K. LucyInsiderSell5,000$10.04$50,200.00View SEC Filing  
8/18/2016Patricia LadyInsiderSell2,000$9.42$18,840.00View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.00View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.00View SEC Filing  
12/15/2015Chemical Co /De/ DowMajor ShareholderSell600,000$11.75$7,050,000.00View SEC Filing  
12/3/2015Patrick K LucyInsiderSell1,500$14.15$21,225.00View SEC Filing  
12/1/2015Bertrand C. LiangCEOSell5,000$14.88$74,400.00View SEC Filing  
12/1/2015Henry W Jr. TalbotVPSell2,000$15.08$30,160.00View SEC Filing  
11/18/2015Patricia LadyCAOSell2,000$14.05$28,100.00View SEC Filing  
11/4/2015Patrick K. LucyinsiderSell1,500$17.54$26,310.00View SEC Filing  
11/2/2015Bertrand C LiangCEOSell5,000$18.01$90,050.00View SEC Filing  
10/2/2015Patrick K LucyInsiderSell1,500$14.98$22,470.00View SEC Filing  
10/1/2015Bertrand C LiangCEOSell5,000$14.78$73,900.00View SEC Filing  
9/3/2015Patricia LadyCAOSell2,000$20.48$40,960.00View SEC Filing  
9/3/2015Patrick K LucyInsiderSell1,500$20.91$31,365.00View SEC Filing  
9/1/2015Bertrand C. LiangCEOSell5,000$21.02$105,100.00View SEC Filing  
7/6/2015Patrick K LucyInsiderSell1,500$19.17$28,755.00View SEC Filing  
7/1/2015Bertrand C LiangCEOSell5,000$19.63$98,150.00View SEC Filing  
6/3/2015Patrick K LucyInsiderSell1,500$20.08$30,120.00View SEC Filing  
6/1/2015Bertrand C LiangCEOSell5,000$18.70$93,500.00View SEC Filing  
5/4/2015Patrick K LucyInsiderSell1,500$13.25$19,875.00View SEC Filing  
5/1/2015Bertrand C LiangCEOSell5,000$13.49$67,450.00View SEC Filing  
4/29/2015Chemical Co /De/ DowMajor ShareholderSell2,232,233$14.57$32,523,634.81View SEC Filing  
4/29/2015James C GaleDirectorSell1,907,767$14.57$27,796,165.19View SEC Filing  
4/2/2015Patrick K LucyInsiderSell1,500$17.62$26,430.00View SEC Filing  
4/1/2015Bertrand C LiangCEOSell5,000$15.27$76,350.00View SEC Filing  
3/4/2015Patrick K LucyInsiderSell1,500$14.36$21,540.00View SEC Filing  
7/29/2014Signet Healthcare Partners AccMajor ShareholderSell380,867$0.31$118,068.77View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pfenex (NYSEMKT:PFNX)
DateHeadline
News IconPfenex Inc PFNX Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NYSEMKT:PFNX)
www.bioportfolio.com - February 20 at 9:30 AM
finance.yahoo.com logoPfenex Inc. to Participate in Panel Discussion at 2017 BIO CEO & Investor Conference (NYSEMKT:PFNX)
finance.yahoo.com - February 10 at 8:11 PM
4-traders.com logoPfenex : Announces Leadership Transition (NYSEMKT:PFNX)
www.4-traders.com - January 25 at 6:00 AM
us.rd.yahoo.com logo8:02 am Pfenex announced that Dr. Bertrand C. Liang has resigned his position as CEO, President, Secretary and as a member of the Board of Directors of the Co (NYSEMKT:PFNX)
us.rd.yahoo.com - January 24 at 7:57 PM
finance.yahoo.com logoPfenex Announces Leadership Transition (NYSEMKT:PFNX)
finance.yahoo.com - January 24 at 8:37 AM
biz.yahoo.com logoPFENEX INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Other Events, Fi (NYSEMKT:PFNX)
biz.yahoo.com - January 24 at 8:37 AM
News IconPfenex Inc PFNX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NYSEMKT:PFNX)
www.bioportfolio.com - January 6 at 5:01 AM
News IconIs Pfenex Inc (PFNX) A Good Stock To Buy? (NYSEMKT:PFNX)
feedproxy.google.com - December 12 at 8:15 AM
capitalcube.com logoETFs with exposure to Pfênex, Inc. : December 2, 2016 (NYSEMKT:PFNX)
www.capitalcube.com - December 2 at 6:52 PM
capitalcube.com logoPfênex, Inc. :PFNX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016 (NYSEMKT:PFNX)
www.capitalcube.com - November 23 at 7:05 PM
finance.yahoo.com logoPfenex (PFNX) Catches Eye: Stock Adds 6.6% in Session (NYSEMKT:PFNX)
finance.yahoo.com - November 17 at 10:45 AM
streetinsider.com logoForm 4 Pfenex Inc. For: Nov 15 Filed by: Lucy Patrick K. (NYSEMKT:PFNX)
www.streetinsider.com - November 16 at 7:05 PM
prnewswire.com logoPfenex Reports Third Quarter 2016 Results and Provides Business Update (NYSEMKT:PFNX)
www.prnewswire.com - November 10 at 9:55 AM
finance.yahoo.com logoEdited Transcript of PFNX earnings conference call or presentation 9-Nov-16 9:30pm GMT (NYSEMKT:PFNX)
finance.yahoo.com - November 10 at 9:55 AM
sg.finance.yahoo.com logoPfenex posts 3Q profit (NYSEMKT:PFNX)
sg.finance.yahoo.com - November 9 at 6:45 PM
biz.yahoo.com logoQ3 2016 Pfenex Inc Earnings Release - After Market Close (NYSEMKT:PFNX)
biz.yahoo.com - November 9 at 9:24 AM
benzinga.com logoPfenex To Report Third Quarter 2016 Results and... (NYSEMKT:PFNX)
www.benzinga.com - October 26 at 6:49 PM
publicnow.com logoPfenex To Report Third Quarter 2016 Results and Provide Business Update on Wednesday, November 9, 2016 (NYSEMKT:PFNX)
www.publicnow.com - October 26 at 6:49 PM
capitalcube.com logoETF’s with exposure to Pfênex, Inc. : October 18, 2016 (NYSEMKT:PFNX)
www.capitalcube.com - October 18 at 12:03 PM
publicnow.com logoPfenex Reports New Employment Inducement Award Under NYSE MKT Listing Rules (NYSEMKT:PFNX)
www.publicnow.com - October 3 at 6:19 PM
sg.finance.yahoo.com logoInsider Q&A: Why so little relief on pricey biologic drugs (NYSEMKT:PFNX)
sg.finance.yahoo.com - September 18 at 6:15 PM
capitalcube.com logoETF’s with exposure to Pfênex, Inc. : August 24, 2016 (NYSEMKT:PFNX)
www.capitalcube.com - August 24 at 6:33 PM
capitalcube.com logoETF’s with exposure to Pfênex, Inc. : August 12, 2016 (NYSEMKT:PFNX)
www.capitalcube.com - August 12 at 6:55 PM
capitalcube.com logoPfênex, Inc. :PFNX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NYSEMKT:PFNX)
www.capitalcube.com - August 11 at 7:17 PM
News IconPfenex Announces Positive Anthrax Vaccine Study Results (NYSEMKT:PFNX)
www.pipelinereview.com - August 9 at 9:59 AM
4-traders.com logoPfenex : reports 2Q loss (NYSEMKT:PFNX)
www.4-traders.com - August 9 at 9:59 AM
rttnews.com logoMESO Gains After Hours, PFNX Gets It Back, CHRS' Humira Biosimilar Meets Goals (NYSEMKT:PFNX)
www.rttnews.com - August 9 at 9:59 AM
finance.yahoo.com logoPfenex to Regain Full Rights to PF582 and Announces Phase 1/2 Results (NYSEMKT:PFNX)
finance.yahoo.com - August 8 at 7:01 PM
cnbc.com logoPfenex reports 2Q loss (NYSEMKT:PFNX)
www.cnbc.com - August 8 at 7:01 PM
prnewswire.com logoPfenex Reports Second Quarter 2016 Results and Provides Business Update (NYSEMKT:PFNX)
www.prnewswire.com - August 8 at 7:01 PM
finance.yahoo.com logoJazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product … (NYSEMKT:PFNX)
finance.yahoo.com - July 28 at 7:03 PM
News IconPotential Mega-Deal for Pfenex (PFNX); Upside Visualized In Ballard Power Systems (BLDP) (NYSEMKT:PFNX)
galaxystocks.com - July 28 at 7:03 PM
publicnow.com logoPfenex To Report Second Quarter 2016 Results and Provide Business Update on Monday, August 8, 2016 (NYSEMKT:PFNX)
www.publicnow.com - July 27 at 8:48 AM
wsj.com logo[$$] Road to Launching 'Biosimilar' Drugs Just Got Longer (NYSEMKT:PFNX)
www.wsj.com - July 13 at 7:38 AM
wsj.com logo[$$] Gormley's Take: Road to Launching 'Biosimilar' Drugs Just Got Longer (NYSEMKT:PFNX)
www.wsj.com - July 13 at 7:30 AM
biz.yahoo.com logoPFENEX INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (NYSEMKT:PFNX)
biz.yahoo.com - July 6 at 5:21 PM
capitalcube.com logoETF’s with exposure to Pfênex, Inc. : June 23, 2016 (NYSEMKT:PFNX)
www.capitalcube.com - June 23 at 1:48 PM
thestreet.com logo6 Breakout Stocks Under $10 Set to Soar (NYSEMKT:PFNX)
www.thestreet.com - May 31 at 7:18 AM

Social

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PFNX."

Where is Pfenex's stock going? Where will Pfenex's stock price be in 2017?

3 brokers have issued 1-year price objectives for Pfenex's shares. Their forecasts range from $14.00 to $22.00. On average, they anticipate Pfenex's share price to reach $18.00 in the next year.

When will Pfenex announce their earnings?

Pfenex is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

Who owns Pfenex stock?

Pfenex's stock is owned by a number of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (16.53%), Dow Chemical Co. DE (7.56%), Perceptive Advisors LLC (3.90%), Marshall Wace LLP (1.25%), FMR LLC (1.17%) and State Street Corp (1.06%). Company insiders that own Pfenex stock include Bertrand C Liang, Chemical Co /De/ Dow, Henry W Jr Talbot, James C Gale, Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc.

Who sold Pfenex stock? Who is selling Pfenex stock?

Pfenex's stock was sold by a variety of institutional investors in the last quarter, including Dow Chemical Co. DE, Franklin Resources Inc., FMR LLC and Allianz Asset Management AG. Company insiders that have sold Pfenex stock in the last year include Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc.

Who bought Pfenex stock? Who is buying Pfenex stock?

Pfenex's stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Oxford Asset Management, Dimensional Fund Advisors LP, Renaissance Technologies LLC, State Street Corp and Marshall Wace LLP.

How do I buy Pfenex stock?

Shares of Pfenex can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pfenex stock cost?

One share of Pfenex stock can currently be purchased for approximately $7.82.


Last Updated on 2/21/2017 by MarketBeat.com Staff